Sichuan Biokin Pharmaceutical Co., Ltd.: Squamous Cell Carcinoma of Head and Neck trials

The registry lists 12 Squamous Cell Carcinoma of Head and Neck studies with Sichuan Biokin Pharmaceutical Co., Ltd. as lead sponsor. 7 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsNot yet recruitingNCT07788950Phase 2
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT07274852Phase 1
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT07232524Phase 1
A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT06469008Phase 1
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT06437522Phase 2
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT06006169Phase 2
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsRecruitingNCT05983432Phase 1
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT06668961Phase 2
A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT05668858Phase 1/2
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCCActive, not recruitingNCT05054439Phase 2
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCCActive, not recruitingNCT05044897Phase 2
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial TumorsActive, not recruitingNCT04603287Phase 1

All Squamous Cell Carcinoma of Head and Neck studies →Sichuan Biokin Pharmaceutical Co., Ltd.: all focus areas →